a6991h-jointfiling
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November
28, 2022
Barclays PLC and
Barclays Bank PLC
(Names
of Registrants)
1 Churchill Place
London E14 5HP
England
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual
reports
under
cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F
Indicate
by check mark whether the registrant by furnishing the
information
contained
in this Form is also thereby furnishing the information to
the
Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes No
x
If
"Yes" is marked, indicate below the file number assigned to the
registrant
in
connection with Rule 12g3-2(b):
This
Report is a joint Report on Form 6-K filed by Barclays PLC and
Barclays
Bank
PLC. All of the issued ordinary share capital of Barclays Bank PLC
is
owned
by Barclays PLC.
This
Report comprises:
Information
given to The London Stock Exchange and furnished pursuant
to
General
Instruction B to the General Instructions to Form 6-K.
EXHIBIT
INDEX
Update
regarding Chief Executive Officer dated 28 November
2022
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, each of
the registrants has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
BARCLAYS
PLC
|
|
(Registrant)
|
Date:
November 28, 2022
|
By: /s/
Garth Wright
--------------------------------
|
|
Garth
Wright
|
|
Assistant
Secretary
|
|
BARCLAYS
BANK PLC
|
|
(Registrant)
|
Date:
November 28, 2022
|
By: /s/
Garth Wright
--------------------------------
|
|
Garth
Wright
|
|
Assistant
Secretary
|
28
November 2022
Barclays PLC
Update regarding Chief Executive Officer
Barclays PLC and Barclays Bank PLC ("Barclays") announces that
its CEO, C.S. Venkatakrishnan, has informed the Barclays Board and
his colleagues that he will be undergoing treatment for Non-Hodgkin
Lymphoma. His letter on this subject is below:
"Dear Colleagues:
I am writing to inform you that I have been diagnosed with
Non-Hodgkin Lymphoma. The good news is that the matter has
been detected early, with scans and biopsies confirming it to be
very localised.
My treatment is at Memorial Sloan Kettering Cancer Center in New
York. The doctors have advised that my prognosis is
excellent, and my condition is curable with their prescribed
regimen. This is likely to last 12 to 16 weeks. During
this period, the company will run normally, and I will continue to
be actively engaged in managing it. However, I will have to
work from home for some periods and not be able to
travel. Fortunately, I have always exercised regularly and am
strong and fit as I commence this treatment.
The Board has been kept apprised of my situation and I am
enormously grateful for their support.
We have a highly capable and seasoned Executive Committee,
supported by a talented senior management team. I am very
confident that we will continue, with your help, to serve our
customers and clients well, and produce strong operating
performance for our shareholders.
I am deeply appreciative, and very proud, of your support and
extraordinary efforts in these volatile times."
- ENDS -
For further information, please contact:
Investor Relations
|
Media Relations
|
Chris Manners
|
Jon Tracey
|
+44 (0)20 7773 2136
|
+44 (0)20 7116 4755
|
|
|
About Barclays
Barclays is a British universal bank. We are diversified by
business, by different types of customer and client, and
geography. Our businesses include consumer banking and
payments operations around the world, as well as a top-tier, full
service, global corporate and investment bank, all of which are
supported by our service company which provides technology,
operations and functional services across the Group. For
further information about Barclays, please visit our
website home.barclays.